 |
Antisense oligonucleotide directed against connexin43 |
|---|---|
| Trade Name | Nexagon |
| Orphan Indication | Persistent corneal epithelial defects |
| USA Market Approval | USA |
| USA Designation Date | 2009-04-27 00:00:00 |
| Sponsor | CoDa Therapeutics, Inc.;10505 Sorrento Valley Road;San Diego, California, 92121 |
